Icagen, Inc. Announces Presentation Related To Senicapoc At The 15th International Inflammation Research Association Conference

RESEARCH TRIANGLE PARK, N.C., Sept. 22, 2008 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today, at the 15th International Inflammation Research Association Conference in Chantilly, Virginia, results from a preclinical study demonstrating effects of senicapoc in isolated human lung mast cells. Senicapoc, the Company's novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, was shown to potently block KCa3.1 potassium currents in isolated human lung mast cells and to reduce the migration of these cells when exposed to an inflammatory stimulus. The Company also presented additional results from a previously reported preclinical study that demonstrate the ability of senicapoc to reverse the antigen-induced increases in airway resistance and airway hyper-reactivity in a sheep model of asthma. These results were presented by Lee Robinette, Ph.D., Senior Research Investigator at Icagen.